Clinical significance of expression of PPP1R105 in hepatocellular carcinoma
- Author:
- No author available
- Journal Title:
- World Chinese Journal of Digestology
- Issue:
- 16
- DOI:
- 10.11569/wcjd.v28.i16.765
- Key Word:
- 肝细胞癌;总生存;无疾病进展生存;生物信息分析;免疫组化
Abstract： 背景 肝细胞癌(hepatocellular carcinoma, HCC)是临床上常见的实体恶性肿瘤,预后较差.本文拟采用生物信息学技术分析PPP1R105基因在肝细胞癌中的表达相关信号通路及其与患者预后关系.同时,采用免疫组织化学法对PPP1R105生物信息数据进行验证.目的 探讨PPP1R10基因(Ki-67或MKI67)在HCC中的表达及其临床意义.方法 在TCGA数据中,检索PPP1R105基因在各个肿瘤组织中的相对表达情况;分析PPP1R105基因在肝细胞癌组织和癌旁组织中的相对表达水平,并比较是否存在差异.应用蛋白相互作用数据库STRING构建PPP1R105基因编码蛋白相互作用网络.比较PPP1R105高低表达组患者无疾病进展生存(disease free survival,DFS)和总生存(overall survival,OS)是否存在差异.选取我院手术治疗的原发性肝细胞癌患者81例进行回顾性分析,采用免疫组织化学法检测肝细胞癌组织中PPP1R105蛋白表达情况,并与患者的临床特征进行相关性分析.结果 PPP1R105基因mRNA在不同肿瘤中表达水平差异并不显著,其表达不具备肿瘤间特异性.在肝细胞癌中,癌组织PPP1R105mRNA表达水平显著高于癌旁正常肝组织(P＜0.05),且表达水平与患者临床分期有关(P＜0.05).蛋白相互作用网络区域聚集指数为0.99,蛋白相互作用网络富集明显(P＜0.01).PPP1R105及其相关基因信号通路主要富集于细胞周期、细胞衰老、病毒致癌及p53信号通路.KIF18B与PPP1R105正相关表达最为显著(rpearson=0.91,P＜0.05);而MCELL基因与PPP1R105负相关表达最为显著(rpearson=-0.59,P＜0.05);PPP1R105高表达组OS (HR=1.90,P＜0.01)和DFS(HR=1.90,P＜0.01)显著低于低表达组.PPP1R105蛋白主要表达于细胞核质及核仁,81例患者中高表达者30例(37.0％).PPP1R105蛋白高表达患者肿瘤大于5 cm及TNM分期Ⅲa期患者比例显著高于MIK67蛋白低表达者(P＜0.05).结论 肝细胞癌患者PPP1R105高表达,其与患者总生存和无疾病进展生存较短有关,可作为肝细胞癌患者预后不良分子标志物.
- [1]覃超群,高枫,黄斌,等.晚期肺癌ki-67表达水平与生存期的相关性研究[J].2019,(3).
- [2]彭绍华,杨剑锋,谢平平,等.肝细胞肝癌组织中survivin和caspase 3、Ki67的表达及意义[J].2005,(3).
- [3]张月严,李强,栗海涛,等.Ki67表达比例对乳腺癌患者预后影响的Meta分析[J].2019,(11).
- [4]Ponomarenko PV.,Waters CL.,Menk FW..Visualization of ULF waves in SuperDARN data - art. no. 1926[J].2003,30(18).
- [5]Rebecca L. Siegel,Kimberly D. Miller,Ahmedin Jemal.Cancer statistics, 2019[J].2019,69(1).
- [6]Zefang, Tang,Chenwei, Li,Boxi, Kang,etc.GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses.[J].2017,(Spec ).
- [7]Mouchli, Mohamad A.,Singh, Siddharth,Loftus, Edward V.,etc.Risk Factors and Outcomes of De Novo Cancers (Excluding Nonmelanoma Skin Cancer) After Liver Transplantation for Primary Sclerosing Cholangitis[J].2017,101(8).
- [8]Ching KA,Wiltshire T,Block D,etc.A gene atlas of the mouse and human protein-encoding transcriptomes[J].2004,101(16).
- [9]Geetanjali R, Kamath,Emanuela, Taioli,Natalia, N Egorova,etc.Liver Cancer Disparities in New York City: A Neighborhood View of Risk and Harm Reduction Factors.[J].2018,8(Spec ).
- [10]Sun, Xiaoming,Bizhanova, Aizhan,Matheson, Timothy D.,etc.Ki-67 Contributes to Normal Cell Cycle Progression and Inactive X Heterochromatin in p21 Checkpoint-Proficient Human Cells[J].2017,37(17).
- [11]Koo Han,Yoo,Taesoo,Choi,Hyung-Lae,Lee.Blood culture for complicated acute pyelonephritis with ureteral stone: are they unnecessary?[J].2018.
- [12]高春.肝癌分子病理流行病学[J].2018,(9).
- [13]Lee, Seokwon,Jung, Younglae,Bae, Youngtae,etc.Prevalence and risk factors of nonalcoholic fatty liver disease in breast cancer patients[J].2017,103(2).
- [14]Martin Fischer,Patrick Grossmann,Megha Padi,etc.Integration of TP53, DREAM, MMB-FOXM1 and RB-E2F target gene analyses identifies cell cycle gene regulatory networks[J].2016,(13).
- [15]Ingo Kausch,Anja Lingnau,Elmar Endl,etc.Antisense treatment against Ki-67 mRNA inhibits proliferation and tumor growth <em>in vitro</em> and <em>in vivo</em>[J].2003,105(5).